title: Malaria vaccines and the new malaria agenda.
abstract: The development of an effective malaria vaccine has taken many decades, but there is now a good chance that the first malaria vaccine will be licensed within the next few years. However, this vaccine (RTS,S) will not be fully effective, and more efficacious, second-generation vaccines will be needed. Good progress is being made in the development of potential vaccines directed at each of the three main stages of the parasite's life cycle, with a variety of different approaches, but many challenges remain, e.g. overcoming the problem of polymorphism in many key parasite antigens. It is likely vaccines that are effective enough to block transmission, and thus contribute to increasing drives towards malaria elimination, will need to contain antigens from different stages of the parasite's life cycle.
authors: Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK. brian.greenwood@lshtm.ac.uk.
authors: B M
authors: BM
authors: Greenwood
authors: G A T
authors: GA
authors: Targett
mesh_terms: D018562:Disease Transmission, Infectious / Q000517:prevention & control; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D008288:Malaria / Q000453:epidemiology* / Q000517:prevention & control* / Q000635:transmission; D017780:Malaria Vaccines / Q000276:immunology*; D010961:Plasmodium / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity*; D011110:Polymorphism, Genetic
chemical_list: D017780:Malaria Vaccines